ArticleScientific reports2017
Modulation of Interleukin-12 activity in the presence of heparin.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Glycosaminoglycans as Polyelectrolytes: Charge, Interactions, and Applications.Chembiochem : a European journal of chemical biology · 2025Review
- Injectable hyaluronic acid-based hydrogel niches to create localized and time-controlled therapy delivery.Materials today. Bio · 2025Article
- Harnessing the Potential of FAP-IL12mut TMEkine for Targeted and Enhanced Antitumor Responses.Molecular cancer therapeutics · 2025Article
- Elucidating the role of carrier proteins in cytokine stabilization within double emulsion-based polymeric nanoparticles.Bioengineering & translational medicine · 2025Article
- An IL-12-Based Nanocytokine Safely Potentiates Anticancer Immunity through Spatiotemporal Control of Inflammation to Eradicate Advanced Cold Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells.Pharmaceutics · 2022Review
- Coacervate-mediated novel pancreatic cancer drug Aleuria Aurantia lectin delivery for augmented anticancer therapy.Biomaterials research · 2022Article
- Injectable Liposome-based Supramolecular Hydrogels for the Programmable Release of Multiple Protein Drugs.Matter · 2022Article
- Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.Frontiers in immunology · 2022Article
- Safety and Pharmacokinetics of Intravesical Chitosan/Interleukin-12 Immunotherapy in Murine Bladders.Bladder cancer (Amsterdam, Netherlands) · 2021Article
- The Antitumor Effect of Heparin is not Mediated by Direct NK Cell Activation.Journal of clinical medicine · 2020Article
- Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- Localized Interleukin-12 for Cancer Immunotherapy.Frontiers in immunology · 2020Review
- The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review.Frontiers in pharmacology · 2020Review
- HS and Inflammation: A Potential Playground for the Sulfs?Frontiers in immunology · 2020Review
- Heparinoid Complex-Based Heparin-Binding Cytokines and Cell Delivery Carriers.Molecules (Basel, Switzerland) · 2019Review
- Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein.Cytokine · 2019Article
- Molecular mechanisms of heparin-induced modulation of human interleukin 12 bioactivity.The Journal of biological chemistry · 2019Article
- The localisation of the heparin binding sites of human and murine interleukin-12 within the carboxyterminal domain of the P40 subunit.Cytokine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Glycosaminoglycans (GAGs), especially heparin and heparan sulfate (HS), modulate the functions of numerous cytokines. The aims of this multidisciplinary research were to characterize heparin binding to interleukin-12 (IL-12) and determine the mechanism(s) by which heparin influences IL-12 bioactivity. Heparin and HS were found to bind human IL-12 (hIL-12) with low micromolar affinity and increase hIL-12 bioactivity by more than 6-fold. Conversely, other GAGs did not demonstrate significant binding, nor did their addition affect hIL-12 bioactivity. Biophysical studies demonstrated that heparin induced only minor conformational changes while size-exclusion chromatography and small angle X-ray scattering studies indicated that heparin induced dimerization of hIL-12. Heparin modestly protected hIL-12 from proteolytic degradation, however, this was not a likely mechanism for increased cytokine activity in vitro. Flow cytometry studies revealed that heparin increased the amount of hIL-12 bound to cell surfaces. Heparin also facilitated hIL-12 binding and signaling in cells in which both hIL-12 receptor subunits were functionally deleted. Results of this study demonstrate a new role for heparin in modulating the biological activity of IL-12.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.